Vaccine approaches and treatment aspects against Crimean Congo hemorrhagic fever

Crimean-Congo hemorrhagic fever [CCHF] is a severe infectious viral disease caused by a tick borne virus which can lead to fatal hemorrhagic disease in humans. It has been reported from some continents including Africa, Asia and Europe. Virus is transmitted to human mainly through tick bite, whose a...

Full description

Saved in:
Bibliographic Details
Published in:Virusdisease 2024-06, Vol.35 (2), p.377-383
Main Authors: Sarmadi, Soroush, Ghalyanchilangeroudi, Arash, Najafi, Hamideh
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Asymptomatic
Biochemistry
Biomedical and Life Sciences
Cell Biology
Crimean hemorrhagic fever
Disease transmission
DNA vaccines
DNA viruses
Drug development
Enzymes
Fever
Genomes
Glycoproteins
Hemorrhagic disease
Infectious diseases
Insect bites
Life Sciences
Medical research
Microbiology
mRNA
Nosocomial infections
Protein Structure
Proteins
Review
Ribavirin
Vaccines
Viral diseases
Viruses
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Crimean-Congo hemorrhagic fever [CCHF] is a severe infectious viral disease caused by a tick borne virus which can lead to fatal hemorrhagic disease in humans. It has been reported from some continents including Africa, Asia and Europe. Virus is transmitted to human mainly through tick bite, whose acquire infection from reservoirs wild and domesticated mammalians and ostriches. Currently no approved vaccine or drug is available for CCHF and prevention is mainly based on biosecurity measures. Ribavirin is the only approved drug that has been used in some countries to treat human disease, however some new studies did not prove the Ribavirin efficacy. Different strategies to design effective vaccines, have been conducted through years, from inactivated virus to nucleotide-based ones including DNA and mRNA vaccines. In this study we review of pioneering vaccine candidate platforms.
ISSN:2347-3584
2347-3517
DOI:10.1007/s13337-024-00868-9